| Issue Date | Title | Author(s) |
| 2018-03-02 | Defining the distinct, intrinsic properties of the novel type i interferon, IFNϵ | Stifter, SA; Matthews, AY; Mangan, NE; Fung, KY; Drew, A; Tate, MD; Soares Da Costa, TP; Hampsey, D; Mayall, J; Hansbro, PM; Minambres, AG; Eid, SG; Mak, J; Scoble, J; Lovrecz, G; DeWeerd, NA; Hertzog, PJ |
| 2021-09-17 | Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. | Christie, MJ; Irving, AT; Forster, SC; Marsland, BJ; Hansbro, PM; Hertzog, PJ; Nold-Petry, CA; Nold, MF |
| 2023-07-20 | Publisher Correction: Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon | Ryan, TAJ; Hooftman, A; Rehill, AM; Johansen, MD; O' Brien, EC; Toller-Kawahisa, JE; Wilk, MM; Day, EA; Weiss, HJ; Sarvari, P; Vozza, EG; Schramm, F; Peace, CG; Zotta, A; Miemczyk, S; Nalkurthi, C; Hansbro, NG; McManus, G; O'Doherty, L; Gargan, S; Long, A; Dunne, J; Cheallaigh, CN; Conlon, N; Carty, M; Fallon, PG; Mills, KHG; Creagh, EM; O' Donnell, JS; Hertzog, PJ; Hansbro, PM; McLoughlin, RM; Wygrecka, M; Preston, RJS; Zasłona, Z; O'Neill, LAJ |
| 2023-06-14 | Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon. | Ryan, TAJ; Hooftman, A; Rehill, AM; Johansen, MD; Brien, ECO; Toller-Kawahisa, JE; Wilk, MM; Day, EA; Weiss, HJ; Sarvari, P; Vozza, EG; Schramm, F; Peace, CG; Zotta, A; Miemczyk, S; Nalkurthi, C; Hansbro, NG; McManus, G; O'Doherty, L; Gargan, S; Long, A; Dunne, J; Cheallaigh, CN; Conlon, N; Carty, M; Fallon, PG; Mills, KHG; Creagh, EM; Donnell, JSO; Hertzog, PJ; Hansbro, PM; McLoughlin, RM; Wygrecka, M; Preston, RJS; Zasłona, Z; O'Neill, LAJ |
